Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary


Home > Formulary : Adult > Chapters > 5. Infections >

BNSSG Adult Joint Formulary

5.7 Treatment of COVID-19

Checked: not set yet by Next Review: not set yet

5.7.1 COVID-19

Neutralising monoclonal antibodies (nMABs) in the treatment of COVID-19

Sotrovimab (Xevudy®) (TLS Red)

  • NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
  • For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here

Casirivimab and Imdevimab (TLS Red)

  • NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Tocilizumab (TLS Red)

  • NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

 

Antivirals in the treatment of COVID-19

Molnupiravir (Lagevrio®) (TLS Red)

  • For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here

Nirmatrelvir and Ritonavir (Paxlovid®) (TLS Red)

  • NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 
  • For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here
  • SPS guidance on medicines interactions with nirmatrelvir and ritonavir (Paxlovid®) to be used alongside the NHSE/I commissioning policy here

Remdesivir (TLS Red)

  • For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here

 

Janus-associated tyrosine kinase (JAK) inhibitors in the treatment of COVID-19

Baricitinib (TLS Red)

  • For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here

 

Contact us

Got a question or comment about the Joint Formulary? 

Please use the email address below to contact us and we will endeavour to respond within 2 working days.